TL;DR

Seattle's immunotherapy and antibody biotech companies need a coverage stack built around immuno-oncology clinical risk, not a generic biotech template. The core program pairs D&O that scales through financing rounds with clinical trial liability sized for first-in-human immunotherapy dosing, plus cyber, IP indemnity to academic licensors, and IP infringement defense for antibody platforms. Products liability enters later, near commercialization rather than at IND.

Seattle immunotherapy & antibody biotech

Insurance for Seattle Immunotherapy & Antibody Biotech Companies

Seattle is one of the world's leading centers for immunotherapy, immuno-oncology, and antibody and antibody-drug-conjugate biotech. The Fred Hutchinson Cancer Center is a globally recognized immunotherapy and bone-marrow-transplant institution, the University of Washington anchors regional research, and the surrounding cluster carries a deep bench in antibody engineering and immune medicine. That concentration produces a distinct risk profile that a generalist biotech policy tends to underserve.

Companies in this vertical are typically clinical-stage, venture-financed, and operating with intellectual property licensed out of academic institutions. The insurance program has to respond to three pressures at once: governance and financing risk as capital arrives, human-subject exposure as immunotherapies move into the clinic, and platform IP that is both a core asset and a litigation target. This page outlines how specialty carriers structure coverage for that combination.

Get a quote Run the Free Analyzer

Last updated 2026-07-13

Cluster shape

The Seattle immunotherapy and antibody cluster

The regional ecosystem spans immuno-oncology developers, antibody and antibody-drug-conjugate platforms, and immune-repertoire and immune-medicine companies, many with research roots at UW or Fred Hutchinson Cancer Center. South Lake Union serves as a dense hub for this activity, keeping founders, licensors, and clinical collaborators in close proximity.

Most of these companies share a common shape: a small clinical-stage team, an academic-license IP foundation, and a pipeline that carries serious biological risk long before any revenue. Underwriters read that shape carefully, because the exposures driving the program are scientific and human-subject exposures rather than commercial ones.

This immunotherapy and antibody angle is deliberately distinct from Seattle's cell-therapy cluster. While the two overlap in immuno-oncology ambition, the coverage triggers differ enough that antibody and immunotherapy developers benefit from a program tuned to their specific trial and platform-IP profile.

Coverage architecture

Coverage the immunotherapy and antibody stack requires

Directors and officers liability becomes effectively mandatory once outside investor capital arrives. Series A through C programs typically run in the $1M-$15M range, stepping up as the company approaches an IPO and its governance, disclosure, and securities exposures grow. Clinical trial liability sits alongside it, sized for immuno-oncology first-in-human dosing, because immunotherapies can carry serious immune-mediated adverse-event profiles that elevate trial exposure relative to more conventional modalities.

Cyber coverage is scoped to the data these companies actually hold: clinical protected health information and sensitive drug master file data. IP indemnity and additional-insured obligations flow to the academic licensor, whether that is UW or Fred Hutchinson Cancer Center, and the program must satisfy the insurance terms written into the license. IP infringement defense protects the antibody or platform intellectual property that anchors company value and is a frequent target of dispute.

Products liability generally activates near commercialization rather than at IND. Carrying heavy products limits during the clinical stage adds cost without matching the actual exposure, so specialty carriers typically phase that coverage in as a candidate approaches market approval and real-world use.

Regulatory + market context

Regulatory and academic-license context

Immunotherapy and antibody programs advance through FDA-regulated pathways, and human-subject research imposes clinical trial obligations that underwriters expect to see reflected in the program, including trial-specific limits and the contractual indemnities owed to sites and collaborators. First-in-human immuno-oncology work draws particular scrutiny given the adverse-event profiles involved.

Because so much of this IP originates in academic institutions, license agreements with UW or Fred Hutchinson Cancer Center often dictate minimum insurance limits, additional-insured status, and indemnity terms. Those clauses effectively set a coverage floor, and aligning the program to them early prevents licensing friction and diligence delays as the company raises capital.

Frequently asked

Common questions from Seattle immunotherapy & antibody biotech operators

How is immunotherapy and antibody biotech insurance different from a generic biotech policy?

A generic biotech policy tends to treat every clinical-stage company the same, but immunotherapy and antibody developers carry a specific risk profile. The clinical trial liability has to account for immune-mediated adverse events, the IP coverage has to address antibody and platform infringement risk, and the academic-license terms behind the IP impose their own insurance requirements. Specialty carriers build the program around those triggers rather than applying a one-size template.

Why do immuno-oncology trials elevate clinical trial liability?

Immunotherapies work by engaging the immune system, and that mechanism can produce serious immune-mediated adverse events, particularly during first-in-human dosing. That elevated biological risk translates into greater human-subject exposure, so clinical trial liability is sized and priced with immuno-oncology dosing in mind rather than the lower-intensity profile of a conventional small-molecule trial.

How should D&O be sized as the company moves through financing rounds?

D&O becomes effectively mandatory once outside investor capital arrives. Series A through C programs commonly run in the $1M-$15M range, with limits stepping up as the company matures. As an IPO approaches, governance, disclosure, and securities exposures increase, and the program is expected to scale accordingly ahead of any public offering.

How do UW or Fred Hutch license terms affect coverage?

When IP is licensed out of UW or Fred Hutchinson Cancer Center, the license agreement frequently specifies minimum insurance limits, additional-insured status for the institution, and indemnity obligations. Those clauses set a practical floor for the program, so the coverage has to be structured to satisfy the license from the outset to avoid friction during licensing and investor diligence.

Biotech insurance practice →Academic-spinout biotech →Seattle cell therapy →Washington state guide →

Free coverage review

A specialist will reach out by end of business day.

Programs placed through A-rated specialty markets. Send your contract, insurance schedule, or current COI - a specialist returns a clause-by-clause read by end of business day.

Get my quote

Specifically for Seattle immunotherapy & antibody biotech operators.

Work emailSo we can send the clause-by-clause review.PhoneOptional. So a specialist can reach you on a tight deadline.CompanySo we route to the right specialist.Company typeDetermines which carriers we approach.MSA stageTells us how urgent the timeline is.Annual revenueOptional. Helps us size the program.Anything else?Optional. What you need help with, deadlines, or context.

Programs placed through A-rated specialty markets. Your specialist handles unlimited certificates of insurance, annual coverage reviews, and claims advocacy.